0.00Open0.00Pre Close0 Volume0 Open Interest13.00Strike Price0.00Turnover170.04%IV-127.67%PremiumDec 20, 2024Expiry Date7.29Intrinsic Value100Multiplier28DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9434Delta0.0515Gamma--Leverage Ratio-0.0044Theta-0.0047Rho0.00Eff Leverage0.0018Vega
Terns Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Terns Announces Proposed Public Offering
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $125 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares. Jefferies, TD Cowen, and UBS Investment Bank are acting as bookrunners for the offering.
Terns intends to...
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
Terns Pharmaceuticals (Nasdaq: TERN)announced positive Phase 1 clinical trial results for TERN-601, its once-daily oral GLP-1R agonist for obesity treatment. The trial showed:
- Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo-adjusted)
- Well-tolerated with no treatment-related dose ...
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals announced new preclinical data supporting their compound TERN-501 in combination with a GLP-1 receptor agonist for treating obesity. The data was presented at the ADA’s 84th Annual Scientific Sessions. TERN-501, a highly selective THR-...
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
No comment yet